Our findings show that once-only measurement of [TIMP-2]•[IGFBP7] in patients with AKI has a good prognostic performance in predicting adverse outcomes such as mortality and a moderate performance in predicting the requirement for RRT. Here, TIMP2 is linked to acute kidney injury.